BIO-RAD LABORATORIES, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.6B | $2.6B | $2.7B | $2.8B | $2.9B |
| Cost of revenue | $1.2B | $1.2B | $1.2B | $1.2B | $1.3B |
| Gross profit | $1.3B | $1.4B | $1.4B | $1.6B | $1.6B |
| Selling, general & administrative | $844.3M | $814.0M | $841.7M | $827.8M | $877.1M |
| Research and development | $275.6M | $295.9M | $247.4M | $256.9M | $260.6M |
| Operating income | $47.2M | $269.0M | $337.8M | $482.6M | $500.3M |
| Interest expense | $49.0M | $48.9M | $49.4M | $38.1M | $1.6M |
| Pretax income | $995.5M | -$2.3B | -$850.1M | -$4.7B | $5.4B |
| Income tax expense | $235.6M | -$498.3M | -$212.8M | -$1.1B | $1.2B |
| Net income | $759.9M | -$1.8B | -$637.3M | -$3.6B | $4.3B |
| Balance Sheet | |||||
| Cash and equivalents | $529.8M | $488.1M | $403.8M | $434.2M | $470.8M |
| Current assets | $2.9B | $3.0B | $3.0B | $3.2B | $2.0B |
| Total assets | $10.6B | $9.4B | $12.3B | $13.5B | $17.8B |
| Current liabilities | $517.0M | $467.8M | $522.8M | $568.7M | $680.9M |
| Total liabilities | $3.1B | $2.8B | $3.6B | $3.9B | $4.1B |
| Stockholders' equity | $7.5B | $6.6B | $8.7B | $9.6B | $13.7B |
| Cash Flow Statement | |||||
| Cash from operations | $532.2M | $455.2M | $374.9M | $194.4M | $669.5M |
| Depreciation and amortization | $165.4M | $151.6M | $145.9M | $137.3M | $137.6M |
| Stock-based compensation | $58.0M | $62.3M | $61.3M | $60.9M | $51.2M |
| Capital expenditure | $157.6M | $165.6M | $156.7M | $112.8M | $133.7M |
| Free cash flow | $374.6M | $289.6M | $218.2M | $81.6M | $535.7M |
| Share repurchases | $295.5M | $203.6M | $428.7M | $215.7M | $50.0M |
| Impairments | $172.8M | $0 | $0 | $0 | $0 |
Shares outstanding 26.8M · Free float 37.6%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.